Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
Evaluating the Efficacy, Compliance, and Patient Satisfaction of a New Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion criteria: * ZSFG patient initially seen in the eye clinic, approved by attending ophthalmologist for cataract surgery in both eyes due to visually significant cataracts, and who elects to have cataract surgery in both eyes. * Patients 18 years of age or older Exclusion criteria: * Patients requiring bilateral simultaneous (same-day bilateral) cataract surgery * Patients with prior history of: endophthalmitis, advanced glaucoma, known history of intraocular pressure elevation due to steroids, prior intraocular surgery, cystoid macular edema/diabetic macular edema/retinal edema noted in the past 12 months prior to cataract surgery * Patients with documented penicillin or cephalosporin allergy or intolerance * Patients requiring combined same day cataract and ophthalmic subspecialty procedure (eg; combined cataract and glaucoma, retina, or cornea surgery). * Patients who are pregnant or breastfeeding
About the study
The current postoperative cataract surgery eye drop regimen used at Zuckerberg San Francisco General Hospital (ZSFG) is a significant burden for its patient population, contributing to high rates of non-adherence and the development of postoperative complications. The investigators propose to replace this complex regimen with a single administration of intraocular antibiotic and subconjunctival steroid at the time of surgery. This pilot study will obtain the preliminary data required to eventually fully evaluate this innovation in postoperative care in a safety-net population with respect to postoperative outcomes, patient compliance, and patient and caregiver satisfaction.
What is being tested
- Dropless Regimen (drug)
- Standard Regimen (drug)
Sponsor: University of California, San Francisco · Participants: 70 · Started: May 31, 2022
Contact the study team
- Sriranjani Padmanabhan, MD · Phone: 415-514-0241
- Nicole Xin, BA · Phone: 628-206-3123
Official record on ClinicalTrials.gov — NCT05157113
Locations in the U.S.
| California | Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG), San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.